When AR is inhibited or when the polyol pathway is blocked, it can therefore be expected that endogenous hepatic fructose generation will be greatly reduced such that fructose-induced lipogenesis in the liver will also be suppressed, thereby leading to the suppression of hepatic steatosis or NAFLD. The gene discussed is AR; the disease is fatty liver disease.